Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study.

Oertel FC, Havla J, Roca-Fernández A, Lizak N, Zimmermann H, Motamedi S, Borisow N, White OB, Bellmann-Strobl J, Albrecht P, Ruprecht K, Jarius S, Palace J, Leite MI, Kuempfel T, Paul F, Brandt AU.

J Neurol Neurosurg Psychiatry. 2018 Jun 19. pii: jnnp-2018-318382. doi: 10.1136/jnnp-2018-318382. [Epub ahead of print]

PMID:
29921610
2.

Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.

Graetz C, Gröger A, Luessi F, Salmen A, Zöller D, Schultz J, Siller N, Fleischer V, Bellenberg B, Berthele A, Biberacher V, Havla J, Hecker M, Hohlfeld R, Infante-Duarte C, Kirschke JS, Kümpfel T, Linker R, Paul F, Pfeuffer S, Sämann P, Toenges G, Weber F, Zettl UK, Jahn-Eimermacher A, Antony G, Groppa S, Wiendl H, Hemmer B, Mühlau M, Lukas C, Gold R, Lill CM, Zipp F.

Mult Scler. 2018 Mar 1:1352458518763541. doi: 10.1177/1352458518763541. [Epub ahead of print]

PMID:
29532745
3.

TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing-remitting multiple sclerosis.

Unterrainer M, Mahler C, Vomacka L, Lindner S, Havla J, Brendel M, Böning G, Ertl-Wagner B, Kümpfel T, Milenkovic VM, Rupprecht R, Kerschensteiner M, Bartenstein P, Albert NL.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1423-1431. doi: 10.1007/s00259-018-3974-7. Epub 2018 Mar 9.

PMID:
29523925
4.

[18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy.

Brendel M, Schönecker S, Höglinger G, Lindner S, Havla J, Blautzik J, Sauerbeck J, Rohrer G, Zach C, Vettermann F, Lang AE, Golbe L, Nübling G, Bartenstein P, Furukawa K, Ishiki A, Bötzel K, Danek A, Okamura N, Levin J, Rominger A.

Front Aging Neurosci. 2018 Jan 17;9:440. doi: 10.3389/fnagi.2017.00440. eCollection 2017.

5.

No need for NMDA receptor antibody screening in neurologically asymptomatic patients with ovarian teratomas.

Trillsch F, Eichhorn P, Oliveira-Ferrer L, Kuempfel T, Burges A, Mahner S, Havla J.

J Neurol. 2018 Feb;265(2):431-432. doi: 10.1007/s00415-017-8717-3. Epub 2017 Dec 22. No abstract available.

PMID:
29273845
6.

Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.

Meinl I, Havla J, Hohlfeld R, Kümpfel T.

Mult Scler. 2018 Jun;24(7):991-994. doi: 10.1177/1352458517731913. Epub 2017 Sep 18.

PMID:
28920764
7.

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.

Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Young KL, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl U, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Kleiter I; NEMOS (Neuromyelitis Optica Study Group).

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):639-647. doi: 10.1136/jnnp-2017-315603. Epub 2017 Jun 1.

8.

In Reply.

Havla J.

Dtsch Arztebl Int. 2017 Apr 28;114(17):299. doi: 10.3238/arztebl.2017.0299b. No abstract available.

9.

Patient-to-patient transmission of natalizumab-associated PML?

Hohlfeld R, Havla J, Kümpfel T.

Mult Scler. 2017 Oct;23(11):1564-1565. doi: 10.1177/1352458517701316. Epub 2017 Mar 20. No abstract available.

PMID:
28318370
10.

Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

Havla J, Warnke C, Derfuss T, Kappos L, Hartung HP, Hohlfeld R.

Dtsch Arztebl Int. 2016 Dec 26;113(51-52):879-886. doi: 10.3238/arztebl.2016.0879. Review.

11.

Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.

Havla J, Kümpfel T, Schinner R, Spadaro M, Schuh E, Meinl E, Hohlfeld R, Outteryck O.

J Neurol. 2017 Jan;264(1):139-151. doi: 10.1007/s00415-016-8333-7. Epub 2016 Nov 14.

PMID:
27844165
12.

Influence of female sex and fertile age on neuromyelitis optica spectrum disorders.

Borisow N, Kleiter I, Gahlen A, Fischer K, Wernecke KD, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Weissert R, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Rückriem L, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Hellwig K; NEMOS (Neuromyelitis Optica Study Group).

Mult Scler. 2017 Jul;23(8):1092-1103. doi: 10.1177/1352458516671203. Epub 2016 Oct 6.

PMID:
27758954
13.

Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, Hellwig K, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; Neuromyelitis Optica Study Group.

Ann Neurol. 2016 Feb;79(2):206-16. doi: 10.1002/ana.24554. Epub 2015 Nov 26.

PMID:
26537743
14.

Late-onset neutropenia during long-term rituximab therapy in neuromyelitis optica.

Plate A, Havla J, Kümpfel T.

Mult Scler Relat Disord. 2014 Mar;3(2):269-72. doi: 10.1016/j.msard.2013.08.001. Epub 2013 Aug 31.

PMID:
25878016
15.

[Immunotherapies for multiple sclerosis : review and update].

Havla J, Kümpfel T, Hohlfeld R.

Internist (Berl). 2015 Apr;56(4):432-45. doi: 10.1007/s00108-015-3668-1. Review. German.

PMID:
25720530
16.

Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.

Hoepner R, Havla J, Eienbröker C, Tackenberg B, Hellwig K, Meinl I, Hohlfeld R, Gold R, Kümpfel T, Kleiter I.

Mult Scler. 2014 Nov;20(13):1714-20. doi: 10.1177/1352458514533398. Epub 2014 May 19.

PMID:
24842961
17.

Unusual natalizumab-associated progressive multifocal leukoencephalopathy starting in the brainstem.

Havla J, Hohlfeld R, Kümpfel T.

J Neurol. 2014 Jan;261(1):232-4. doi: 10.1007/s00415-013-7191-9. Epub 2013 Nov 26. No abstract available.

PMID:
24276521
18.

Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?

Havla J, Kleiter I, Kümpfel T.

Ther Clin Risk Manag. 2013;9:361-9. doi: 10.2147/TCRM.S41552. Epub 2013 Oct 3. Review.

19.

The major brain endocannabinoid 2-AG controls neuropathic pain and mechanical hyperalgesia in patients with neuromyelitis optica.

Pellkofer HL, Havla J, Hauer D, Schelling G, Azad SC, Kuempfel T, Magerl W, Huge V.

PLoS One. 2013 Aug 9;8(8):e71500. doi: 10.1371/journal.pone.0071500. eCollection 2013.

20.

L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.

Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H.

Neurology. 2013 Sep 3;81(10):865-71. doi: 10.1212/WNL.0b013e3182a351fb. Epub 2013 Aug 7.

PMID:
23925765
21.
22.

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.

Havla J, Tackenberg B, Hellwig K, Meinl I, Krumbholz M, Seitz F, Eienbröker C, Gold R, Hohlfeld R, Kleiter I, Kümpfel T.

J Neurol. 2013 May;260(5):1382-7. doi: 10.1007/s00415-012-6808-8. Epub 2012 Dec 25.

PMID:
23266894
23.

Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab "infusion group".

Havla J, Berthele A, Kümpfel T, Krumbholz M, Jochim A, Kronsbein H, Ryschkewitsch C, Jensen P, Lippmann K, Hemmer B, Major E, Hohlfeld R.

Mult Scler. 2013 Aug;19(9):1213-5. doi: 10.1177/1352458512466165. Epub 2012 Nov 1.

PMID:
23124790
24.

Treatment with 4-aminopyridine improves upper limb tremor of a patient with multiple sclerosis: a video case report.

Schniepp R, Jakl V, Wuehr M, Havla J, Kümpfel T, Dieterich M, Strupp M, Jahn K.

Mult Scler. 2013 Apr;19(4):506-8. doi: 10.1177/1352458512461394. Epub 2012 Oct 15.

PMID:
23069878
25.

[2012: Update on diagnosis and treatment of multiple sclerosis].

Havla J, Kümpfel T, Hohlfeld R.

Dtsch Med Wochenschr. 2012 Apr;137(17):894-9. doi: 10.1055/s-0032-1304927. Epub 2012 Apr 10. Review. German. No abstract available. Erratum in: Dtsch Med Wochenschr. 2012 May;137(20):1072.

PMID:
22492476
26.

Familial Mediterranean fever-associated mutation pyrin E148Q as a potential risk factor for multiple sclerosis.

Kümpfel T, Gerdes LA, Wacker T, Blaschek A, Havla J, Krumbholz M, Pöllmann W, Feneberg W, Hohlfeld R, Lohse P.

Mult Scler. 2012 Sep;18(9):1229-38. doi: 10.1177/1352458512437813. Epub 2012 Feb 15.

PMID:
22337722
27.

Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.

Havla JB, Pellkofer HL, Meinl I, Gerdes LA, Hohlfeld R, Kümpfel T.

Arch Neurol. 2012 Feb;69(2):262-4. doi: 10.1001/archneurol.2011.1057.

PMID:
22332194
28.

[Multiple sclerosis: can therapy delay ongoing disability?].

Havla J, Pellkofer HL, Hohlfeld R, Kümpfel T.

MMW Fortschr Med. 2011 Apr 7;153(14):63-6. Review. German. No abstract available.

PMID:
21966873
29.

Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.

Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, Bittner R, Canis M, Meinl E, Hohlfeld R, Kuempfel T.

Neurology. 2011 Apr 12;76(15):1310-5. doi: 10.1212/WNL.0b013e3182152881.

PMID:
21482945
30.

Lässt sich die Behinderung hinausschieben? : Multiple Sklerose.

Havla J.

MMW Fortschr Med. 2011 Apr;153(14):63-7. doi: 10.1007/BF03368107. German. No abstract available.

PMID:
27369838
31.

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.

Havla J, Gerdes LA, Meinl I, Krumbholz M, Faber H, Weber F, Pellkofer HL, Hohlfeld R, Kümpfel T.

J Neurol. 2011 Sep;258(9):1665-9. doi: 10.1007/s00415-011-5996-y. Epub 2011 Mar 23.

PMID:
21431380
32.

[Progress of therapy in patients with multiple sclerosis].

Kümpfel T, Havla J, Hohlfeld R.

MMW Fortschr Med. 2010 Mar 4;152(9):42-4. German. No abstract available.

PMID:
20384096
33.

Cartilage tissue engineering for auricular reconstruction: in vitro evaluation of potential genotoxic and cytotoxic effects of scaffold materials.

Havla JB, Lotz AS, Richter E, Froelich K, Hagen R, Staudenmaier R, Kleinsasser NH.

Toxicol In Vitro. 2010 Apr;24(3):849-53. doi: 10.1016/j.tiv.2009.12.005. Epub 2009 Dec 11.

PMID:
20005288
34.

Cytotoxic and genotoxic effects of matrices for cartilage tissue engineering.

Lotz AS, Havla JB, Richter E, Frölich K, Staudenmaier R, Hagen R, Kleinsasser NH.

Toxicol Lett. 2009 Oct 28;190(2):128-33. doi: 10.1016/j.toxlet.2009.06.880. Epub 2009 Jul 17.

PMID:
19616607
35.

[Reproducibility and reliability of phonovibrograms. Quantification of healthy vocal fold vibrations].

Havla J, Döllinger M, Eysholdt U, Lohscheller J.

HNO. 2009 Feb;57(2):160-8. doi: 10.1007/s00106-008-1748-4. German.

PMID:
19183918
36.

Evaluation of the mutagenic effects of myosmine in human lymphocytes using the HPRT gene mutation assay.

Havla JB, Hill CE, Abdel-Rahman SZ, Richter E.

Food Chem Toxicol. 2009 Jan;47(1):237-41. doi: 10.1016/j.fct.2008.11.008. Epub 2008 Nov 13.

PMID:
19041922

Supplemental Content

Support Center